Cabaletta Bio, Inc.

For the period ended Mar 31, 2026. Filed May 14, 2026.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Mar 31, 2026 · Filed May 14, 2026

CABA$1.45-3.3%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Condensed Consolidated Statements of Stockholders’ Equity

(in thousands, except share amounts)

	Common Stock
	Shares	Amount	AdditionalPaid-in Capital	Accumulated Deficit	TotalStockholders’ Equity
Balance—December 31, 2024	50,743,101	$1	$501,435	$(349,101)	$152,335
Stock-based compensation	—	—	5,161	—	5,161
Net loss	—	—	—	(35,943)	(35,943)
Balance—March 31, 2025	50,743,101	$1	$506,596	$(385,044)	$121,553

Condensed Consolidated Statements of Stockholders’ Equity

(in thousands, except share amounts)

	Common Stock
	Shares	Amount	AdditionalPaid-in Capital	Accumulated Other Comprehensive Income (Loss)	Accumulated Deficit	TotalStockholders’ Equity
Balance—December 31, 2025	100,479,323	$1	$628,982	$25	$(516,957)	$112,051
Issuance of common stock from ATM offering, net of sales agent commission and fees	8,055,260	—	22,568	—	—	22,568
Issuance of common stock upon exercise of common stock warrants	2,775,100	—	6,938	—	—	6,938
Issuance of common stock in connection with exercise of stock options	15,113	—	32	—	—	32
Stock-based compensation	—	—	5,256	—	—	5,256
Net unrealized losses on available-for-sale securities	—	—	—	(25)	—	(25)
Net loss	—	—	—	—	(43,515)	(43,515)
Balance—March 31, 2026	111,324,796	$1	$663,776	$—	$(560,472)	$103,305

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.